Running a pre-launch compliance check before a campaign goes live

In Europe, there is no single EMA-run advertising police force. Advertising to consumers for prescription drugs is banned outright under EU law (Directive 2001/83/EC), and advertising to healthcare professionals is regulated at the national level, often through industry self-regulatory bodies like the UK's PMCPA (Prescription Medicines Code of Practice Authority), which enforces the ABPI Code.

The core rule set every asset must survive

Three regulatory pillars show up in nearly every MLR checklist:

1. Fair balance. Any claim of efficacy must be accompanied by comparably prominent risk information. A TV ad claiming a drug "controls symptoms" cannot bury the side-effect list in tiny disclaimer text at the bottom.

2. Substantiation. Every claim needs a citable source, usually the approved product label or a peer-reviewed trial. "Fewer flare-ups" needs a number and a study, not a feeling.

3. Off-label promotion ban. Marketing cannot promote uses, populations, or dosing not included in the drug's approved label. This is one of the most heavily enforced areas: several billion-dollar settlements in the US pharmaceutical industry have stemmed from off-label promotion allegations (for example, historical cases involving Pfizer and GlaxoSmithKline, both publicly documented in Department of Justice settlements).

Walking the checklist: a real asset, step by step

Imagine a digital banner ad for a Type 2 diabetes drug, running only in the US, aimed at healthcare professionals (HCPs) on a clinical portal.

Step 1: Claim-by-claim mapping.

Every factual statement gets tagged to its source. "Reduces HbA1c by an average of 1.2%" must trace to a specific clinical trial table, with the citation logged in the review software (most large pharma companies use platforms like Veeva Vault PromoMats for this).

Step 2: Indication check.

Confirm the ad only discusses the approved indication. If the drug is approved for adults with Type 2 diabetes, an image implying use in adolescents is a red flag, even if unintentional.

Step 3: Fair balance layout check.

Legal checks the visual hierarchy: is the risk information (black box warnings, common side effects) at least as visible as the benefit claim? A common objection: benefit claims in bold 24-point font, risk information in 8-point gray text. That imbalance alone can trigger an Untitled Letter.

Step 4: Comparator claims.

If the ad says "more effective than [Competitor Drug]," medical must confirm this is from a head-to-head trial, not two separate trials compared informally. Indirect comparisons without direct trial data are a frequent MLR rejection reason.

Step 5: Channel-specific rules.

Social media snippets have character limits that make fair balance hard to fit. FDA guidance (non-binding but influential) suggests that if you cannot fit adequate risk information in the post itself, you need a direct, unbroken link to it. This is why you often see pharma tweets or LinkedIn posts that look oddly sparse, then link out immediately.

Step 6: Reference and legal archive.

Legal confirms the piece is archived per SOP retention rules (in the US, typically for the life of the promotional campaign plus a required retention window, often several years, per company policy and FDA recordkeeping expectations).

Where campaigns actually get stuck

Based on publicly available OPDP letters, the most frequent objection categories are consistent year over year:

• Overstating efficacy ("cures" language where only symptom management is approved)
• Minimizing or omitting risk information
• Unsubstantiated superiority claims
• Broadening the implied patient population beyond the label

A useful pattern for marketers: if a claim feels like the *strongest* possible version of the truth, it is often the version MLR will flag first. The safest claims are the most literal restatements of trial data.

A simple pre-submission gut check

Before an asset even reaches formal MLR queue, marketers can self-screen with four questions:

1. Can I point to the exact page and table in the approved label or trial publication for every claim?

2. Is my risk information visually equal in prominence to my benefit claim?

3. Would this claim survive being read aloud next to the FDA-approved label, with no additional context?

4. If this ran in a country with stricter DTC (direct-to-consumer advertising) rules, like anywhere in the EU, would it even be legal to run at all?

That fourth question matters more each year as global campaigns get built once and localized. The US allows DTC prescription drug advertising (one of only two countries in the world to do so, alongside New Zealand); the EU does not. A campaign asset built for a US audience often cannot simply be translated for European HCP or patient channels; it needs a parallel compliance pass.

Building anticipation into your workflow, not just review

Smart marketing teams do not treat MLR as a gate at the end; they treat it as a filter built into creative development. Practical habits:

• Pre-clear claim language with medical affairs before creative production starts, not after the asset is designed. Redesigning a finished asset because a headline claim fails substantiation wastes budget and timeline.
• Maintain a "claims library" of pre-approved, MLR-cleared statements that creative teams can draw from, reducing repeat rejections on the same underlying facts.
• Run a mock MLR review internally before formal submission, especially for first-of-kind formats (a new social platform, a new interactive format) where no precedent exists in your claims library.

🎬 [VIDEO: "FDA Regulation of Prescription Drug Advertising" - youtube.com - search for FDA OPDP or industry compliance channel explainers on how drug ad claims are reviewed and enforced, useful for seeing real Warning Letter examples discussed]

Key Takeaways

• MLR (Medical, Legal, Regulatory) review is the mandatory internal checkpoint before any pharma promotional asset launches; in the US it anticipates scrutiny from FDA's OPDP, in Europe from national bodies like the UK's PMCPA.
• Three pillars drive almost every objection: fair balance between benefit and risk information, substantiation of every claim against approved data, and staying strictly within the approved label (no off-label promotion).
• The US permits direct-to-consumer prescription drug advertising; the EU largely bans it, so global campaigns need separate compliance passes, not simple translation.
• Building claim substantiation and fair-balance checks into creative development, not just at final review, prevents costly last-minute redesigns and launch delays.
• The strongest-sounding version of a claim is often the riskiest; literal restatements of trial data are the safest starting point for any pharma marketing asset.